You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

February 21, 2014

Web Version  |  Share with a colleague

Facebook Like   Twitter Tweet

Today's Headlines

Northera approved for NOH

FDA approved droxidopa (Northera, Chelsea Therapeutics) capsules for the treatment of neurogenic orthostatic hypotension.
» Full article

Surprising rate of opioid use among pregnant women

More than 14% of pregnant women were prescribed opioids for pain at some time during their pregnancy, according to a study published online in Anesthesiology. » Full article

Continuing Education

New CPE series: MTM Considerations for Adult Patients with CVD

Drug Topics kicks off a new CPE series, MTM Considerations for Adult Patients with Cardiovascular Disease, which will include 12 knowledge-based activities worth up to 24 credits. The goal of the first activity, “MTM essentials for cholesterol management,” will empower pharmacists to utilize current understanding of cholesterol management to improve patient care. To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.


Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

EDITOR'S PICK

Lawsuits mount over bleeding risks of dabigatran

Boehringer Ingelheim is facing lawsuits in the United States over claims that dabigatran etexilate mesylate (Pradaxa) capsules, a blood-thinner used to reduce the risk of stroke and blood clots in people with atrial fibrillation not caused by a heart valve problem, causes severe and fatal bleeding. » Full article

 

Related Articles

February FDA drug approvals

Gestational diabetes screening should take place at 24 weeks

RESOURCES

Drug Watch

Latest Clinical News

 
Powered by Modern Medicine Advanstar Medical Communications Group